Selection of Rilpivirine Resistant HIV-1 in a Seroconverter on Long-acting Rilpivirine (TMC278LA) from the Lowest Dose Arm of the SSAT 040 Trial

AIDS Research and Human RetrovirusesVol. 30, No. S1 PrEP: Self-testing, Safety and ModelingSelection of Rilpivirine Resistant HIV-1 in a Seroconverter on Long-acting Rilpivirine (TMC278LA) from the Lowest Dose Arm of the SSAT 040 TrialKerri J. Penrose, Urvi M. Parikh, Kristen A. Hamanishi, Constantinos Panousis, Laura Else, David Back, Marta Boffito, Akil Jackson, and John W. MellorsKerri J. PenroseUniversity of Pittsburgh, Pittsburgh, PA, United StatesSearch for more papers by this author, Urvi M. ParikhUniversity of Pittsburgh, Pittsburgh, PA, United StatesSearch for more papers by this author, Kristen A. HamanishiUniversity of Pittsburgh, Pittsburgh, PA, United StatesSearch for more papers by this author, Constantinos PanousisUniversity of Pittsburgh, Pittsburgh, PA, United StatesSearch for more papers by this author, Laura ElseUniversity of Liverpool, Liverpool, United KingdomSearch for more papers by this author, David BackUniversity of Liverpool, Liverpool, United KingdomSearch for more papers by this author, Marta BoffitoSSAT Research, Chelsea & Westminster Hospital, London, United KingdomSearch for more papers by this author, Akil JacksonSSAT Research, Chelsea & Westminster Hospital, London, United KingdomSearch for more papers by this author, and John W. MellorsUniversity of Pittsburgh, Pittsburgh, PA, United StatesSearch for more papers by this authorPublished Online:30 Oct 2014https://doi.org/10.1089/aid.2014.5127.abstractAboutSectionsView articleView Full TextPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"Selection of Rilpivirine Resistant HIV-1 in a Seroconverter on Long-acting Rilpivirine (TMC278LA) from the Lowest Dose Arm of the SSAT 040 Trial." AIDS Research and Human Retroviruses, 30(S1), p. A69FiguresReferencesRelatedDetailsCited ByPre-Exposure Prophylaxis to Prevent HIV Infection: Current Status, Future Opportunities and Challenges12 February 2015 | Drugs, Vol. 75, No. 3 Volume 30Issue S1Oct 2014 InformationCopyright 2014, Mary Ann Liebert, Inc.To cite this article:Kerri J. Penrose, Urvi M. Parikh, Kristen A. Hamanishi, Constantinos Panousis, Laura Else, David Back, Marta Boffito, Akil Jackson, and John W. Mellors.Selection of Rilpivirine Resistant HIV-1 in a Seroconverter on Long-acting Rilpivirine (TMC278LA) from the Lowest Dose Arm of the SSAT 040 Trial.AIDS Research and Human Retroviruses.Oct 2014.A69-A69.http://doi.org/10.1089/aid.2014.5127.abstractPublished in Volume: 30 Issue S1: October 30, 2014PDF download